Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review Fatemeh VazirianSara SamadiAmir Hooshang Mohammadpour Review Article 30 May 2022 Pages: 1 - 6
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies Wen Wee MaJenny J. LiAntonio Jimeno Original Article 22 June 2022 Pages: 7 - 17
Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML) Romain SechaudKaren SinclairDhrubajyoti Pathak Original Article 25 June 2022 Pages: 19 - 27
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis Mourad HamimedPierre LeblondJoseph Ciccolini Original Article 25 June 2022 Pages: 29 - 44
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia Liu-Hua LiaoYi-Qiao ChenLi-Bin Huang Original Article 27 June 2022 Pages: 45 - 52
Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations Wenyuan XiongSofia Friberg HietalaRainer Strotmann Original Article Open access 30 June 2022 Pages: 53 - 69
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies Maarten van EijkHuixin YuAlwin D. R. Huitema Original Article Open access 07 July 2022 Pages: 71 - 82
A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan Kenichi IshizawaMasahiro YokoyamaMichinori Ogura Original Article Open access 07 July 2022 Pages: 83 - 95
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature J. M. van Berge HenegouwenH. van der WijngaartH. Gelderblom Short Communication Open access 22 May 2022 Pages: 97 - 104
